News
MHRA grants Innovation Passports to three novel drugs
The MHRA has awarded Innovation Passports to three drugs that could offer a step forwards in treating lung cancer, Huntington's, and Alzheimer's.
R&D
Europe’s growing vector-borne disease threat: Are we keeping...
In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.
News
argenx agrees Unnatural takeover deal worth up to $1.15bn
argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.
News
Novartis' pelacarsen fail raises questions for other drugs
The data from Novartis' disappointing cardiovascular outcomes trial with Lp(a)-targeting pelacarsen have been revealed, leaving cardiologists puzzled.
News
Inflammation-focused Rezera sets terms for IPO
Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
